公司2024 年收入706.7 百万元,同比+461%。其中,2024 年耐赋康收入353.4百万元,同比+1581%,依嘉收入352.8 百万元,同比+256%。2024 年毛利率74.6%,去年同期72.7%。剔除无形资产摊销后,2024 年毛利率82.9%,去年同期79.9%。2024 年归母净利润-1041.4 百万元,去年同期-844.5 百万元。耐赋康国内持续放量,未来进入肾病指南巩固...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.